Parallel Advisors LLC Acquires Shares of 15,324 AstraZeneca PLC $AZNCF

Parallel Advisors LLC acquired a new stake in shares of AstraZeneca PLC (OTCMKTS:AZNCF) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 15,324 shares of the company’s stock, valued at approximately $2,689,000.

Several other institutional investors have also bought and sold shares of the business. Mascoma Wealth Management LLC purchased a new stake in shares of AstraZeneca in the fourth quarter valued at $46,000. Elyxium Wealth LLC purchased a new stake in shares of AstraZeneca in the fourth quarter valued at $102,000. Redmont Wealth Advisors LLC purchased a new stake in shares of AstraZeneca in the fourth quarter valued at $122,000. Valley Wealth Managers Inc. purchased a new stake in shares of AstraZeneca in the fourth quarter valued at $144,000. Finally, Twin Peaks Wealth Advisors LLC purchased a new stake in shares of AstraZeneca in the fourth quarter valued at $208,000. Institutional investors own 40.87% of the company’s stock.

AstraZeneca Price Performance

Shares of AZNCF opened at $187.10 on Friday. AstraZeneca PLC has a twelve month low of $122.26 and a twelve month high of $195.00. The company’s fifty day simple moving average is $187.10 and its 200-day simple moving average is $185.66.

AstraZeneca Company Profile

AstraZeneca (OTCMKTS:AZNCF) is a global biopharmaceutical company that focuses on the discovery, development, manufacturing and commercialization of prescription medicines. The company’s research and development efforts are concentrated in three main therapeutic areas: oncology; cardiovascular, renal and metabolism; and respiratory, inflammation and autoimmunity. AstraZeneca’s product portfolio includes targeted therapies for lung and breast cancers, novel agents for heart failure and chronic kidney disease, and inhaled treatments for asthma and chronic obstructive pulmonary disease.

The company was formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group, creating one of the world’s largest pharmaceutical firms.